On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Subscribe With Confidence

Stocks to Buy Now (STBN) is Here to Protect Your Privacy and Inbox.

Your privacy and inbox are safe. What does this mean? Stocks to Buy Now via AWeber responsibly manages email marketing campaigns as follows:

  • STBN will send you email if you give them permission to do so (by subscribing to their mailing list). We will respect your permission.
  • STBN will only send you email that is related to what you subscribed to and why you subscribed.
  • STBN will abide by AWeber’s anti-spam rules and anti-spam laws like CAN-SPAM.
  • You can unsubscribe whenever you want with a click of your mouse.

“What If I Want To Unsubscribe?”

At the end of every email you receive from this website you will see an unsubscribe link. Click on that link and you will see an unsubscribe page with two columns marked “Subscribed” and “Unsubscribed”. Click on the button in the “Unsubscribed” column. We will immediately unsubscribe you!

How Does Stocks to Buy Now Prevent Spam and Protect Inboxes?

  • Our email partner AWeber reviews customers’ mailing lists with a variety of automatic tests.
  • Our email partner AWeber manually reviews mailing lists for any signs of irresponsible emailing.

This two-pronged approach has helped keep spammers off AWeber ever since we started managing email in 1998.

To make sure we can keep them off, we share ideas with others in several email industry and anti-spam groups like the Messaging Anti-Abuse Working Group, the Anti-Phishing Working Group and the Online Trust Alliance.

 

 

From Our Blog

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Helomics Leverages Cutting-Edge Tech and Datasets to Improve Cancer Outcomes

May 22, 2020

POAI subsidiary Helomics helps oncologists individualize cancer treatment using patient-derived tumor models to improve outcomes Helomics’ tumor genomic and drug response database is one of the largest in the world with over 150,000 tumors across 137 cancer types Expected CAGR of 10.3% from 2018-2024 for oncology segment of precision medicine industry The relationship between a […]

Rotate your device 90° to view site.